Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

RegenxBio: An analyst and investor event focused on the firm’s ophthalmology program.

February 15, 2019 0

RegenxBio (RGNX), a clinical-stage gene therapy firm with a proprietary NAV® Technology Platform, will host an analyst and investor …

Exelixis’ excellent scientific and financial accomplishments

February 13, 2019 0

Exelixis’ (EXEL) financial results for the fourth quarter and full year 2018 are as inspiring as they are …

Portola: On the right track

February 12, 2019 0

Portola Pharmaceuticals (PTLA) announced full results from ANNEXA-4, Phase 3b/4 trial of its Factor Xa inhibitor antidote Andexxa® in …

Successful results were announced by uniQure for its gene therapy, AMT-061, on hemophilia B patients

February 11, 2019 0

The United States FDA granted Breakthrough Therapy Designation to AMT-061. The European Medicines Agency gave it …

End of the Year Decisions ~ Part 3

February 10, 2019 0

Prohost Letter #428 End of the Year Decisions ~ Part 3 In Part 3 of this …

ImmunoGen’s Report and Standing. Why Biogen Is Experiencing a Selloff

February 8, 2019 0

ImmunoGen & Biogen News About ImmunoGen ImmunoGen (IMGN) is a creator and developer of antibody-drug conjugates (ADCs) …

Halozyme signs another license agreement this time with argenx

February 5, 2019 0

Halozyme Therapeutics (HALO) and argenx (ARGX) announced a global collaboration and license agreement offering argenx the right to use …

RegenxBio product RGX-181 has been granted FDA Rare Pediatric Disease Designation for Batten Disease Condition known as CLN2

February 1, 2019 0

FDA Granted Rare Pediatric Disease Designation for RegenxBio’s Product RGX-181 for CLN2 RegenxBio RegenxBio (RGNX), a …

Merck’s superior accomplishments

February 1, 2019 0

Merck (MRK) announced its Q4 2018 financial results. The firm outperformed itself and delighted us with regard …

Agenus fincances through Tokenization. Amgen’s critics hit hard. Why BioTime could thrive on OncoCyte news

January 30, 2019 0

AGENUS Agenus (AGEN) announced the upcoming launch of its Biotech Electronic Security Token (BEST); the first digital security …

OncoCyte liquid biopsy proves its accuracy and superiority in the differential diagnoses of Lung Cancer

January 29, 2019 0

Can a liquid biopsy test be accurate enough for physicians to rely on in differentiating between …

Now You See It, Now You Don’t

January 28, 2019 0

Now You See it, Now You Don’t Deliberate Omissions of Real Facts Real facts might be …

End of the Year Decisions Part 2

January 24, 2019 0

Prohost Letter #427 End of the Year Decisions ~ Part 2 As a result of the unexpected …

CompuGen demonstrates the importance of its product COM701 targeting PVRIG in immunotherapy

January 22, 2019 0

Data published in Cancer Immunology Research indicate monotherapy and combination opportunities for COM701, a first-in-class cancer …

Lipocine’s product, LPCN-1144, has promising results in decreasing the risk of NASH in non-alcoholic fatty liver disease

January 17, 2019 0

Lipocine (LPCN), a specialty pharmaceutical company, announced that an approximately eight-week top-line study using LPCN 1144 …

The FDA committee voted 19 to 1 in favor of approving Amgen’s & UCB’s new osteoporosis product Evenity

January 17, 2019 0

On January 8, 2019 the osteoporosis monoclonal antibody Evenity (romosozumab) developed by Amgen and UCB was …

Another drug approval for Exelixis. Why Alnylam’s stock is under pressure today

January 15, 2019 0

More good news came from Exelixis (EXEL). It was expected by many but not by those who …

End of the Year Decisions ~ Part 1

January 15, 2019 1

Prohost Letter #426 End of the Year Decisions ~ Part 1 We decided to make this …

Why the new approval of Exelixis’ blood pressure drug Minnebro in Japan is important

January 9, 2019 0

Exelixis collaborator, Daiichi Sankyo, Receives Regulatory Approval for MINNEBRO™ (Esaxerenone) Tablets for Hypertension in Japan Exelixis …

Japan approved Gilead’s product Epclusa®. See Also: A collaboration agreement with Yuhan

January 8, 2019 0

Gilead Sciences (GILD) has news that begins with an announcement today that Japan’s Ministry of Health, Labour and …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

RegenxBio: An analyst and investor event focused on the firm’s ophthalmology program.

Exelixis’ excellent scientific and financial accomplishments

Portola: On the right track

Successful results were announced by uniQure for its gene therapy, AMT-061, on hemophilia B patients

End of the Year Decisions ~ Part 3

ImmunoGen’s Report and Standing. Why Biogen Is Experiencing a Selloff

Halozyme signs another license agreement this time with argenx

RegenxBio product RGX-181 has been granted FDA Rare Pediatric Disease Designation for Batten Disease Condition known as CLN2

Merck’s superior accomplishments

Agenus fincances through Tokenization. Amgen’s critics hit hard. Why BioTime could thrive on OncoCyte news

OncoCyte liquid biopsy proves its accuracy and superiority in the differential diagnoses of Lung Cancer

Now You See It, Now You Don’t

End of the Year Decisions Part 2

CompuGen demonstrates the importance of its product COM701 targeting PVRIG in immunotherapy

Lipocine’s product, LPCN-1144, has promising results in decreasing the risk of NASH in non-alcoholic fatty liver disease

The FDA committee voted 19 to 1 in favor of approving Amgen’s & UCB’s new osteoporosis product Evenity

Another drug approval for Exelixis. Why Alnylam’s stock is under pressure today

End of the Year Decisions ~ Part 1

Why the new approval of Exelixis’ blood pressure drug Minnebro in Japan is important

Japan approved Gilead’s product Epclusa®. See Also: A collaboration agreement with Yuhan